OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

Summary by AI BETAClose X

OKYO Pharma Limited announced its participation in the virtual BTIG Biotechnology Conference 2026 on July 28-29, 2026. The company, which is developing investigational therapies for neuropathic corneal pain and anterior segment eye diseases, plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for neuropathic corneal pain.

Disclaimer*

UK 100

Latest directors dealings